Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Accelerated Fertility Treatment Leads To Shortened Time To Pregnancy And Cost Savings
A major new trial recently published in the journal Fertility and Sterility shows that for couples beginning infertility treatments, an accelerated path to in-vitro fertilization (IVF) can offer a shorter time to pregnancy, cost savings of nearly $10,000, and a lowered risk of multiple births.

ISTA Pharmaceuticals Announces Positive Results For Phase 2 Study Of Low-Dose Bromfenac In Dry Eye Disease
ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), announced positive results from a proof-of-concept Phase 2 clinical study in subjects with dry eye disease (keratoconjuctivitis sicca) using a new, proprietary, low-dose formulation of bromfenac, the active ingredient in Xibrom(R) (bromfenac ophthalmic solution) 0.09%. The study achieved statistical significance in the primary endpoint of the objective sign of conjunctival staining (Lissamine Green test) as compared to baseline. The study also achieved statistical significance on the objective sign of corneal staining (Fluorescein test) as compared to baseline. Patients also achieved statistically significant improvements in subjective symptoms measured by the Ocular Surface Disease Index (OSDI) and improvement in patients" most bothersome ocular symptoms.
News of the day
MicroRNAs Help Control HIV Life Cycle
Scientists at Burnham Institute for Medical Research (Burnham) have discovered that specific microRNAs (non-coding RNAs that interfere with gene expression) reduce HIV replication and infectivity in human T-cells. In particular, miR29 plays a key role in controlling the HIV life cycle. The study suggests that HIV may have co-opted this cellular defense mechanism to help the virus hide from the immune system and antiviral drugs. The research was published today in the journal Molecular Cell.
Medical Devices

American Psychiatric Association Endorses Commitment To Closing The Medicare "Doughnut Hole"

The American Psychiatric Association (APA) commended the Senate Finance Committee, the Obama administration and the nation"s pharmaceutical companies today for addressing the Medicare coverage gap in prescription drug plans for America"s seniors. The coverage gap, known as the Medicare "doughnut hole," excludes coverage for the annual costs of prescription medications that exceed $2,700 but don"t reach $6,154, a gap that APA president Alan Schatzberg called "an excessive burden to those over 65 and those who are chronically disabled, including those suffering from mental illnesses." Under the new agreement on the part of Congress and PhRMA, the largest organization representing the pharmaceutical industry, drug companies will provide $80 billion to cover up to 50 percent of the cost of brand-name medications that fall through the gap in Medicare"s Part D prescription program. The agreement is being discussed as part of the major health care reform legislation being considered by Congress. "Although this is a first step, it is a step in the direction of providing high-quality, affordable health care to all Americans," Dr. Schatzberg said. "The APA recognizes that full prescription coverage is an integral part of any meaningful health care reform and applauds the effort to eliminate one of the most glaring deficiencies in Medicare." "We hope to see this agreement take effect as part of a package that includes the comprehensive and universal health care coverage that the American people need and deserve," Dr. Schatzberg said. American Psychiatric Association


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009